Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Sold by Seven Eight Capital LP

Seven Eight Capital LP lessened its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 61.5% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 7,101 shares of the company’s stock after selling 11,341 shares during the period. Seven Eight Capital LP’s holdings in Apellis Pharmaceuticals were worth $272,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of APLS. Future Financial Wealth Managment LLC acquired a new stake in shares of Apellis Pharmaceuticals in the first quarter valued at approximately $29,000. BI Asset Management Fondsmaeglerselskab A S bought a new stake in Apellis Pharmaceuticals during the 1st quarter valued at $89,000. nVerses Capital LLC raised its stake in Apellis Pharmaceuticals by 300.0% during the 2nd quarter. nVerses Capital LLC now owns 2,800 shares of the company’s stock valued at $107,000 after acquiring an additional 2,100 shares in the last quarter. CWM LLC boosted its position in Apellis Pharmaceuticals by 299.9% during the 2nd quarter. CWM LLC now owns 4,151 shares of the company’s stock worth $159,000 after acquiring an additional 3,113 shares during the period. Finally, CWA Asset Management Group LLC bought a new position in shares of Apellis Pharmaceuticals in the fourth quarter worth $205,000. 96.29% of the stock is currently owned by institutional investors.

Apellis Pharmaceuticals Stock Up 0.6 %

Shares of Apellis Pharmaceuticals stock opened at $32.72 on Tuesday. The company has a quick ratio of 4.18, a current ratio of 5.08 and a debt-to-equity ratio of 1.73. Apellis Pharmaceuticals, Inc. has a 12-month low of $31.00 and a 12-month high of $73.80. The firm has a market capitalization of $3.97 billion, a PE ratio of -9.46 and a beta of 0.88. The stock’s fifty day moving average is $37.72 and its 200-day moving average is $43.32.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.03. The company had revenue of $199.70 million during the quarter, compared to analyst estimates of $190.89 million. Apellis Pharmaceuticals had a negative net margin of 52.99% and a negative return on equity of 138.32%. The business’s quarterly revenue was up 110.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.02) earnings per share. Equities analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.29 earnings per share for the current year.

Insider Activity at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, Director A. Sinclair Dunlop sold 37,000 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $36.23, for a total transaction of $1,340,510.00. Following the sale, the director now directly owns 100,000 shares of the company’s stock, valued at approximately $3,623,000. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 6.80% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. JPMorgan Chase & Co. cut their price objective on shares of Apellis Pharmaceuticals from $64.00 to $57.00 and set an “overweight” rating on the stock in a research note on Friday, September 13th. HC Wainwright dropped their price target on shares of Apellis Pharmaceuticals from $92.00 to $83.00 and set a “buy” rating on the stock in a research report on Friday, August 2nd. Wedbush increased their price objective on shares of Apellis Pharmaceuticals from $38.00 to $41.00 and gave the company a “neutral” rating in a report on Friday, August 9th. Robert W. Baird lowered their price objective on shares of Apellis Pharmaceuticals from $96.00 to $92.00 and set an “outperform” rating on the stock in a research note on Monday. Finally, UBS Group cut their target price on Apellis Pharmaceuticals from $85.00 to $83.00 and set a “buy” rating for the company in a research report on Friday, August 9th. Four investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $70.53.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).